Therefore, before the use of PLD, carefully asking patients whether there is a gallstone-related history, referencing the baseline ALT and AST-related biochemical indicators, may be helpful for the prevention of MSHFS and the relevant adjustments of PLD dose. This evidence concerns the gene GPT and gallstones.